nature portfolio

E Al-Jibury M Merkenschlager Corresponding author(s): <u>D Rueckert</u>

Last updated by author(s): <u>4 July 2023</u>

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

Statistics

For	all st	atistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.		
n/a	Cor	Confirmed		
	×	The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement		
x		A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly		
	×	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.		
X		A description of all covariates tested		
	×	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons		
	×	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)		
	×	For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Give P values as exact values whenever suitable.		
X		For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings		
x		For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes		
	×	Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated		
		Our web collection on statistics for biologists contains articles on many of the points above.		

Software and code

Policy information about availability of computer code

 Data collection
 Data was collected from the following sources: NIPBL and NCAPH2 deletion in liver Hi-C: GEO GSE93431; CTCF degron Hi-C in neuronal

 progenitor cells: GEO GSE94452
 Thymocyte Hi-C: GEO GSE199059; RAD21 ChIP-seq: GEO GSM2740561, SMC3 ChIP-seq: GEO GSM2740563;

 CTCF ChIP-seq: Suppl. Table 2 from Kubo et al., 2021 (ref. 27)
 CTCF ChIP-seq: Suppl. Table 2 from Kubo et al., 2021 (ref. 27)

Data analysis Custom code used in this manuscript is available here https://github.com/ea409/twins_hic.git

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

Hi-C, Micro-C, and ChIP-seq data analysed in this study are publicly available: NIPBL and NCAPH2 deletion in liver Hi-C: GEO GSE93431; CTCF degron Hi-C in neuronal progenitor cells: GEO GSE94452 Thymocyte Hi-C: GEO GSE199059; RAD21 ChIP-seq: GEO GSM2740561, SMC3 ChIP-seq: GEO GSM2740563; CTCF ChIP-seq: Suppl. Table 2 from Kubo et al., 2021 (ref. 27)

Human research participants

Policy information about studies involving human research participants and Sex and Gender in Research.

Reporting on sex and gender	N/A
Population characteristics	N/A
Recruitment	N/A
Ethics oversight	N/A

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

🗶 Life sciences 🗌 Behavioural & social sciences 🗌 Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	Experimental study design was not part of this paper, we analysed public data sets
Data exclusions	Hi-C replicates were selected according to similarity in sequencing depth as described in the paper
Replication	The findings described in this study were replicated using five random seeds for the Twins machine learning algorithm
Randomization	No randomisation was performed
Blinding	No blinding was performed

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

nature portfolio | reporting summary

Materials & experimental systems

- n/a Involved in the study

 Involved in the study
- Eukaryotic cell lines
- Palaeontology and archaeology
- Animals and other organisms
- 🗶 🗌 Clinical data
- **X** Dual use research of concern

Methods

- n/a Involved in the study
- ChIP-seq

 Flow cyto
- Flow cytometry
- MRI-based neuroimaging